MATINAS BIOPHARMA HOLDINGS, INC. Available-for-sale Securities, Amortized Cost Basis
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Available-for-sale Securities, Amortized Cost Basis of $29.44 million as of 2021-06-30, per its 10-Q filed 2021-08-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2021-08-10
- 2021-06-30: Available-for-sale Securities, Amortized Cost Basis $29.44M.
- 2021-03-31: Available-for-sale Securities, Amortized Cost Basis $37.15M.
- 2020-12-31: Available-for-sale Securities, Amortized Cost Basis $46.02M.
- 2020-09-30: Available-for-sale Securities, Amortized Cost Basis $55.36K.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2021-06-30 | $29.44M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $37.15M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $46.02M 10-Q · filed 2021-08-10 |
| 2020-09-30 | $55.36K 10-Q · filed 2020-11-06 |
| 2020-06-30 | $52.58K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $60.57K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $5.61M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |